RxDoctor Payments Data

Alberto Ramos, MD

Sleep Medicine · Miami, FLNPI 1215149265

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,876 of the $8,424 with a category attached, or 81.6%. 11 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 52.5% of the total. Reporting peaked in 2024 at $4,583 and has fallen 94.1% since, to $271 in 2025.

$8,424in general payments, 2019–2025

Across 45 payments — averaging $187.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$4K
  • ZOLL Respicardia, Inc.$2K
  • Biogen$800
  • Harmony Biosciences LLC$480
  • Resmed Corp$239
  • Axsome Therapeutics, Inc.$157
  • plus $327 from 5 others
$120,408in research payments, 2019–2025

Across 1 payment — averaging $120,408 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Jazz Pharmaceuticals Inc.$120K

What the payments were for

  • Consulting fees$6,87682%
  • Food & beverage$1,28815%
  • Education$2613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,424 in reported general payments places this provider in the 75th percentile of 77 sleep medicine providers in Florida.

See all sleep medicine providers in Florida

Medicare billing

Part B allowed, 2024
$76,455
Medicare patients
471
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelsomraSuvorexant14$6,280
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine14$603
Zolpidem Tartrate27$190
Gabapentin24$133
Eszopiclone14$129
Clonazepam12$72

Paid to pharmacies, not to this prescriber.

Other sleep medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →